We invite you to join us for a guest webinar on Inherency in Anticipation and Obviousness presented by Sterne Kessler’s Gaby Longsworth, director, Biotechnology & Chemical Practice Group and Robert Millonig, director, Biotechnology & Chemical Practice Group.
Date: Thursday 25 June
Time: 09:30-10:30 AEST
Place: Online webinar via Zoom
Inherency, either in the context of anticipation or obviousness, has been a common basis of Examiner's rejections at the USPTO and in PTAB challenges for biotechnology and pharmaceutical inventions. It is also commonly used as an invalidity defense to infringement in US litigation.
Gaby Longsworth and Robert Millonig will discuss the development of this doctrine, recent Federal Circuit cases, as well as strategies to overcome inherency rejections or PTAB challenges. Examples to be discussed include inherency in formulations, method of treatment, pharmacokinetic, and polymorph inventions.
Gaby and Robert each have more than 20 years of experience representing clients in patent preparation and prosecution, PTAB proceedings, and litigation and bring a unique perspective having represented both innovator and generic pharma clients over their careers.
Gaby L. Longsworth, Ph.D., is a director in Sterne Kessler's Biotechnology & Chemical Practice Group and is the chairperson of the firm's Diversity Committee. She is sought out by biopharmaceutical companies world-wide for her insights and knowledge of intellectual property and Hatch-Waxman law.
In her practice, Gaby counsels international biopharmaceutical clients in all areas of patent procurement and strategy, including domestic and foreign patent preparation and lifecycle management. Her practice is primarily focused on biotherapeutics, small molecules, biologics, immunotherapy, antibody technologies, microbiome-based technologies, synthetic biology, DNA amplification/PCR, diagnostics, vaccines, viral vectors and drug delivery.
Robert C. Millonig, Ph.D. is a director in the Biotechnology & Chemical Practice Group. He has significant experience developing and analyzing complex multi-patent portfolios for marketed innovator and generic pharmaceutical products. His approach to resolving legal issues revolves around reaching the solution that best meets the client's business needs, rendering more than 5,000 opinions in the pharmaceutical space alone. Bob counsels clients in various intellectual property matters including patent validity and infringement analysis, freedom to operate, patentability investigations and FDA/ANDA practice. He is versed in the interplay between FDA regulations and patent law and has successfully co-counseled on major litigation involving patent challenges.
|Tags:||patents, US patents|